The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, has disclosed the purchase of 1,200 equity shares (0.05% of total share capital) through the open market on March 25, 2026. The acquisition was done along with Persons Acting in Concert (PACs), which include family members. Before the purchase, the promoter group's holding stood at 14,63,000 shares (64.10%), and after the acquisition it has risen to 14,64,200 shares (64.15%). The total equity share capital of the company is 22,82,400 shares. The disclosure was filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
This is a very small incremental purchase (0.05%) by the promoter, slightly increasing promoter holding from 64.10% to 64.15%. It signals promoter confidence in the company but is too minor to materially impact the stock price or change the shareholding structure.